Sequana Medical has marked a significant milestone in the treatment of patients with liver disease by performing the first commercial implantation of its innovative alfapump® device in the United States at Mount Sinai Hospital in New York City. This groundbreaking procedure took place on November 24, 2025, highlighting a pivotal moment for both the company and the medical community in addressing complications arising from liver conditions.
The alfapump® system is designed to manage fluid buildup in patients suffering from conditions such as liver cirrhosis. It works by automatically draining excess fluid from the abdominal cavity, thereby alleviating discomfort and improving patients’ quality of life. This advancement is particularly relevant for individuals who are not suitable candidates for more invasive treatments or surgeries.
Mount Sinai Hospital has been recognized as a leading institution in the field of hepatology, making it an ideal site for this significant implementation. The first patient to receive the alfapump® implant expressed enthusiasm about the potential benefits of the device, which aims to reduce repeated hospital visits and enhance overall well-being.
Significance of the Alfapump® Technology
The introduction of the alfapump® in the United States aligns with Sequana Medical’s mission to revolutionize care for patients with liver disease. According to the company, the device represents a major step forward in managing ascites—a common complication of liver disease characterized by fluid accumulation. This innovative technology allows for a more patient-centered approach, emphasizing convenience and comfort.
In addition to improving patient outcomes, the alfapump® is expected to have a positive impact on healthcare systems by potentially decreasing the costs associated with frequent hospitalizations. The device allows patients to manage their symptoms at home while maintaining their independence.
Dr. Shlomi Cohen, Chief Executive Officer of Sequana Medical, stated, “Today’s successful implantation at Mount Sinai Hospital is a testament to our commitment to improving the lives of patients with liver disease. We are excited about the positive impact that the alfapump® can have on patient care in the United States.”
Future Prospects and Market Expansion
The successful implantation of the alfapump® at Mount Sinai Hospital is just the beginning of Sequana Medical’s expansion into the U.S. market. The company plans to collaborate with additional hospitals and healthcare providers to increase accessibility to this innovative treatment.
As the prevalence of liver disease continues to rise globally, the demand for effective treatment solutions is more crucial than ever. Sequana Medical is poised to play a significant role in meeting this need, with the alfapump® offering a novel solution to a challenging medical issue.
With the U.S. launch underway, the company anticipates further developments in clinical applications and potential enhancements to the alfapump® technology. As they continue to innovate, Sequana Medical remains focused on its goal of providing better outcomes for patients battling liver disease.
This landmark event at Mount Sinai Hospital underscores the importance of continued advancements in medical technology and the potential for improved healthcare delivery in the future. The alfapump® represents not just a device, but a new hope for many patients seeking relief from the burdens of liver-related complications.
